 PITTSBURGH, May 19, 2022 GLOBE NEWSWIRE -- Krystal Biotech, Inc. the Company NASDAQ: KRYS, the leader in redosable gene therapy, is pleased to present new data entitled GEM-3: phase 3 safety and immunogenicity results of beremagene geperpavec B-VEC, an investigational, topical gene therapy for dystrophic epidermolysis bullosa DEB at the Society for Investigative Dermatology 2022 Annual Meeting, taking place May 18-21 in Portland, Oregon. 